MRFR Year End Sale
High Potency APIs (HPAPI) Market Research Report - Global Forecast till 2030

High Potency APIs (HPAPI) Market Size, Growth and Trends Analysis By Product (Biotech, Synthetic), By Type (Novel, Innovative, Generic) and By Therapeutic Area (Oncology, Glaucoma, Hormonal) – Forecast to 2030

ID: MRFR/Pharma/5216-HCR | December 2022 | Region: Global | 100 Pages         

High Potency APIs Market

High Potency APIs Market is expected grow USD 47,772.70 million at a CAGR 8.90% during the forecast 2020-2030

Segmentation

By Product Biotech Synthetic
By Type Novel Innovative Generic
By Therapeutic Area Oncology Glaucoma Hormonal
By Region Americas Europe Asia Pacific Middle East Africa

Key Players

  • Teva Pharmaceuticals
  • SAFC
  • Carbogen Amics
  • Bristol-Myers Squibb
  • Asymchem
  • Lonza
  • Bayer AG
  • Boehringer Ingelheim
  • Sanofi

Drivers

  • Increasing demand for high potency APIs
  • Growing prevalence of different types of cancer
Speak to Analyst Request a Free Sample

High Potency APIs Market Overview
 
As per the market analysis by MRFR, the high potency APIs market will rake USD 47.77 billion in revenues while expanding with an 8.90% CAGR in the 2022-2030. The shift toward the use of highly powerful active pharmaceutical ingredients (HPAPIs) has resulted in a pipeline of more effective medicines that require lower doses and have fewer adverse effects, which is driving the market forward. The market has been stimulated to a large part by increased investments by enterprises in the production of HPAPIs. Partnerships and collaborations with major contract manufacturing organizations throughout the world are also boosting the high potency API business. The rising occurrence of various types of cancer around the world is also propelling the market forward. The rise of targeted therapy approaches in the treatment of various disorders is projected to boost the market for high potency APIs significantly.
 
The growing demand for high-potency APIs in emerging economies like China, Japan, and India might be attributed to increased awareness and evolving healthcare systems. Increased demand for pharmaceuticals (oncology and antibody-drug conjugates), increased focus on precision medicine and high potency APIs, and technological developments in high potency API manufacturing are some of the reasons driving market expansion. Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. The fundamental components of these medications are high-potency APIs. As the number of cancer cases increases, so will the demand for cancer treatments.

High Potency APIs Market Key Players


The high potency API market is shaped by principal contenders such as



  • Teva Pharmaceuticals

  • SAFC

  • Carbogen Amics

  • Bristol-Myers Squibb

  • Asymchem

  • Lonza

  • Bayer AG

  • Boehringer Ingelheim

  • Sanofi


High Potency APIs Market Segmental Analysis


The segmentation of the high potency APIs market is carried out to ensure better understanding.


By Product



  • Biotech

  • Synthetic


By Type



  • Novel

  • Innovative

  • Generic


By Therapeutic Area



  • Oncology

  • Glaucoma

  • Hormonal


By Region



  • Americas

  • Europe

  • Asia Pacific

  • Middle East

  • Africa


Report Overview


The report by MRFR extend an in-depth study of the current status of the market, industry trends, and a thorough study of the macro and micro economic elements that will possibly motivate the market insights. The report also contains a market review of the key segments in the market such as product, type and therapeutic applications. A revenue analysis covering biotech and synthetic APIs is also presented in the report. The significant therapeutic areas identified in the report are Oncology, Glaucoma and Hormonal. The regional analysis of the market covers regions such as North America, Asia Pacific, Europe, and the Rest of the World.


High Potency APIs Market Report Coverage


The report on high potency APIs market globally covers aspects such as forecast, historical market trends, market dynamics, market value by region as well as by country-level analysis for every individual market segment, key player’s market share analysis, segmentation, and market factor analysis which contains supply chain and Porter’s five forces analysis of the market.

Recent Development


Pfizer bought Amplyx Pharmaceuticals, Inc., a privately held firm focused on the discovery of medicines, in April 2021. The company manufactures many medications, including Fosmanogepix (a fungal inhibitor), which requires high-potency APIs and increases the growth of the High Potency APIs (HPAPI) Market.
 
Novartis agreed to buy GSK's cephalosporin antibiotics business in February 2021, bolstering its global leadership position in antibiotics. Because GSK's cephalosporin antibiotics business requires High Potency APIs, the High Potency APIs (HPAPI) Market will rise as a result of the high demand for these products.

High Potency APIs Market Research Methodology


The research methodology at Market Research Future follows a well-planned approach that ensures effective data collection. The research methodology combines an efficient balance of primary research and secondary research techniques that promote extensive data discovery. The utilization of innovative solutions in studying market conditions and trends further enhances the end product substantially. The incorporation of insights that have the potential of shaping the market’s development in the upcoming period further improves the quality of the reports. Moreover, the incorporation of top up and bottom down approaches additionally augments the report quality. The accuracy of the data collected ensures that the information presented is actionable as well as advantageous to our clients. The analysis of important contenders shaping the market and their future trajectories will additionally enhance the knowledge value gained from our reports.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 47.77 billion
  CAGR   8.90%
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, Type, Therapeutic Area,
  Geographies Covered   Americas, Europe, Asia Pacific, Middle East, Africa
  Key Vendors   Teva Pharmaceuticals, SAFC, Carbogen Amics, Bristol-Myers, Squibb, Asymchem, Lonza, Bayer AG, Boehringer Ingelheim, Sanofi
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers

  • Increasing demand for high potency APIs
  • Growing prevalence of different types of cancer


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The high potency APIs market is projected to grow at an 8.90% CAGR between 2020-2030.

    The high potency APIs market predicted to touch USD 47,772.70 million by 2030.

    North America is projected to command the largest share in the high potency APIs market.

    The biotech segment will lead the high potency APIs market.

    Lack of regulatory framework may limit market growth.